For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Health NZ’s review is an acknowledgement of the crucial role of screening in protecting women’s health
Health NZ’s review is an acknowledgement of the crucial role of screening in protecting women’s health

In response to last night’s announcements that Health NZ and Wellington’s district health boards are carrying out reviews into breast screening and mammogram delays, Breast Cancer Foundation issued the following statement
Ah-Leen Rayner, chief executive of Breast Cancer Foundation NZ, said: “Health NZ’s review is an acknowledgement of the crucial role of screening in protecting women’s health and we welcome the appointment of Dale Bramley, who is highly respected across the sector, to undertake this work.
“I strongly hope that ‘quality’ includes meeting timeliness targets. The Wellington situation is a painful reminder that delayed mammograms put women at risk, and right now there’s a backlog of 50,000 overdue mammograms nationally. It’s horribly ironic that days after a Budget which delivered mammoth healthcare investment, a major problem in screening has been admitted, yet no money was allocated to improving the service.
“I’m very hopeful this process will result in breast screening participation being added to the Government’s Health System Indicators, given that breast cancer is the leading cause of death for women under 65 in Aotearoa – that’s the best way to ensure the equity and quality the review is looking for.”